Medicinova (MNOV) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed OS Therapies (OSTX) over the past year, gaining 26.2% versus a loss of 20.6%. OS Therapies is the larger company by market cap ($77.2 million vs $76.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | OSTX |
|---|---|---|
| Share price | $1.55 | $1.65 |
| Market cap | $76.29M | $77.23M |
| 1-day change | +0.65% | +1.85% |
| YTD return | +17.56% | +15.71% |
| 1-year return | +26.23% | -20.59% |
| 5-year return | -59.69% | — |
| Forward P/E | — | 4.76 |
| EPS (TTM) | $-0.21 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $2.25 |
| 52-week low | $1.17 | $1.15 |
| Distance from 52-week high | -60.26% | -26.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +432.26% | +415.15% |
| Average volume | 322.57K | 586.70K |
| Shares outstanding | 49.22M | 46.81M |
| Employees | 6 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed OSTX by 46.8 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
MNOV vs OSTX FAQ
Which is bigger, Medicinova or OS Therapies?
OS Therapies (OSTX) is larger, with a market capitalization of $77.23M compared with $76.29M for Medicinova (MNOV).
Which stock has performed better over the past year, MNOV or OSTX?
MNOV returned +26.23% over the past 12 months, compared with -20.59% for OSTX (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and OS Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.